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Abstract 
Background: Alcohol withdrawal syndrome (AWS) affects 31% of ICU patients and leads to 
notable increases in morbidity and mortality. Current first line management typically involves 
the use of benzodiazepines (BZD), though historically, therapeutic ethanol (EtOH) was often 
used. Concerns surrounding the side effect profile of BZD, combined with the continued use of 
EtOH in the setting of AWS, have sparked renewed interest in therapeutic EtOH. This review 
analyzes the recent literature surrounding the use of EtOH in patients suffering from AWS in the 
intensive care unit (ICU) setting. 
Methods:  An extensive search was performed using the databases EBMR, MEDLINE-Ovid, 
and Web of Science. The following keywords were used: alcohol, withdrawal, ethanol, delirium, 
and seizure. The search also necessitated studies to have at least one of the following terms: 
intensive care unit, ICU, inpatient, trauma, or critical care. The results were then reviewed for 
quality based on GRADE criteria. 
Results:  The query above generated 494 results that were reviewed for relevancy. Two studies 
met inclusion criteria, both of which were non-blinded, randomized, controlled trials with 
patients being treated for AWS in the ICU using EtOH. One study found mild benefit to using 
EtOH, while the other study found current therapy with BZD to be superior. Quality of the 
studies was either low or very low according to GRADE profile.  
Conclusion:  It is unclear whether patients benefit from EtOH, either as an adjunct or as mono-
therapy, in the management of AWS compared to use of BZD. More research is needed to 
determine the efficacy of therapeutic EtOH.  
Keywords: Alcohol withdrawal syndrome, delirium, seizure, ethanol, intensive care unit, 
inpatient, critical care 
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Use of Therapeutic Ethanol for Patients with Acute Alcohol 
Withdrawal Syndrome in the Intensive Care Unit 
BACKGROUND 
 Alcohol withdrawal syndrome (AWS) is a problematic and dangerous 
complication that affects up to 31% of patients across intensive care unit (ICU) 
settings.1 Its symptomatology begins with disorientation, agitation, and tachycardia, 
which can often progress to delirium tremens (DT), seizures, hallucinations, 
cardiovascular collapse, and even death.2,3 Chronic alcohol use and subsequent AWS 
is associated with increased morbidity and mortality due to elevated risk of infection, 
sepsis, and countless other complications as shown in Table I.4,5  
While AWS is detrimental to patient care, it also has a notable impact on 
healthcare associated costs. In one retrospective review of trauma patient visits 
spanning nearly 5 years, patients who experienced AWS incurred average hospital 
charges that were nearly 3 times higher than patients who did not experience AWS. 
Patients suffering from AWS also spent, on average, 4.28 more days in the ICU and 
required significantly more invasive procedures compared to non-AWS patients.5 
Historically, ethanol (EtOH) has been used in the management of AWS, though 
in recent times, it has largely been replaced by benzodiazepines (BZD) as the first line 
treatment of choice. With this shift in treatment approach has come criticism of 
adverse effects of BZD, namely that it increases the risk of excess sedation, 
 8 
respiratory depression, immune system down-regulation, drug induced delirium, and 
subsequent drug dependence and abuse. 2,4,6-8 Advocates of BZD for treatment of 
AWS suggest that administering EtOH to alcohol dependent patients reinforces their 
addictive behavior, which can be misconstrued as providers condoning their continued 
alcohol abuse.3,10  
As a treatment modality, many studies1,6,8 have shown EtOH to be both a safe 
and effective way to rapidly improve AWS symptoms. Proponents of therapeutic 
EtOH note that previous studies, which demonstrate EtOH as being ineffective, have 
often been confounded by improper dosing that didn’t reflect patient body weight.1 
Dissenters of therapeutic EtOH note its association with increased risk of gastric 
irritation, drug interactions, and hepatic injury, all in the setting of having both a 
narrow therapeutic index and variable rate of hepatic elimination. 3,4  
Despite the shift towards BZD use, EtOH remains on the formulary at more 
than 66% of major teaching hospitals in the United States, and use of therapeutic 
EtOH varies significantly from provider to provider.6,9 Though some academic 
reviews, notably “Ethanol for alcohol withdrawal: The end of an era,” 10 suggest a 
consensus of the literature surrounding therapeutic EtOH, its continued widespread 
use indicates there is not a consensus in clinical practice for the management of a 
particularly common and problematic complication in critical care medicine.  
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METHODS 
An extensive search was performed using the literature databases EBMR, 
MEDLINE-Ovid, and Web of Science, using the keywords: alcohol, withdrawal, 
ethanol, delirium, and seizure. In order to identify proper disease management 
settings, the search also necessitated studies to have one of the following terms: 
trauma, intensive care unit, ICU, inpatient, or critical care. The search was then 
narrowed to English language studies that had been performed within the past 10 
years. The remaining studies were then reviewed for quality based on GRADE 
criteria.12 
RESULTS 
Based on the search performed above, 494 results were generated. From there, 
studies were reviewed for relevancy and duplicate results were removed. A total of 2 
studies (Weinberg et al11, AWARE study9) were selected for inclusion based on 
comparison of treatment efficacy for EtOH versus BZD in the inpatient setting. Study 
GRADE Profile is included in Table II. Summary of findings is included in Figure I 
and II.  
Weinberg et al 
 During 2007, Weinberg et al11 conducted a non-blinded, randomized, 
controlled trial over the course of 15 months with the goal of evaluating BZD 
compared to therapeutic EtOH for management of AWS. Prospective enrollees for the 
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study were selected from patients being admitted to the trauma ICU, who reported 
daily alcohol intake of 5 or more alcoholic beverages per day for the previous 6 
months. Patients with anticipated hospital stay of less than 4 days were excluded.11 
 Patients meeting inclusion criteria were randomized into therapeutic groups for 
either BZD or EtOH management using computerized coin flip simulation. Those in 
the EtOH therapy group received initial EtOH 50mL/hr IV infusion, were evaluated 
regularly using the Riker Sedation Agitation Scale (RSAS), and had EtOH dose 
adjustments with aim of RSAS score of 4 (a score that represents a patient who is 
calm and cooperative; see Appendix A). Those in the BZD therapy group received 
diazepam 5mg every 6 hours, were regularly evaluated using RSAS, and had BZD 
dose adjustments for target RSAS score of 4.11 
 Of the 58 patients who met inclusion criteria, 26 were assigned to the EtOH 
group and 24 were assigned to the BZD group. Eight patients were excluded from the 
study based on exclusion criteria related to age, comorbidities, past medical history, 
and ability to provide informed consent. Additionally, 1 patient opted to withdraw 
from the study, and 1 patient was removed from the study due to receiving additional 
BZD beyond study protocol. There was 1 patient in the EtOH therapeutic arm that 
failed treatment despite reaching max dosing of EtOH (200mL/hr) and required 
additional BZD therapy to control symptoms.11  
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Despite expecting EtOH to be the more successful therapeutic treatment, the 
authors state they found BZD to be superior in the management of AWS. Overall, the 
EtOH arm of treatment had significantly more deviations from RSAS score of 4 
(p=0.020) with the majority of deviations falling in the category of insufficient 
sedation (meaning there was increased patient agitation). All patients were 
successfully weaned from AWS medications.11  
AWARE Study 
 During 2013, Fullwood et al9 conducted a non-blinded, randomized, controlled 
trial with the goal of evaluating BZD as mono-therapy versus BZD with adjunctive 
EtOH in the management of AWS. Prospective enrollees for the study were patients 
who were admitted to the cardiac ICU following a myocardial infarction (MI) and 
were at risk for AWS (as determined by both stated alcohol consumption and scoring 
a 2 or greater on the CAGE alcohol screening survey).9 
Patients meeting inclusion criteria were randomized into either BZD or BZD 
with EtOH therapeutic groups via computer-generated randomization. Of the 57 
patients who fulfilled inclusion criteria, 29 were selected for the BZD mono-therapy 
group and 28 were selected for the BZD with adjunctive EtOH group. All participants 
completed the study except 1 patient death in the BZD group, which was attributed to 
MI.9 
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Patients in the BZD mono-therapy group received lorazepam 2mg IV every 6 
hours, were evaluated regularly for sedation levels based off a modified Ramsey 
Scale, and had BZD dose maintained at 2mg IV every 4 hours to maintain sedation. 
Dosing adjustments were permitted to maintain appropriate level of sedation.9  
Patients in the BZD with EtOH adjunct group received enteral preparations of 
half of their stated daily EtOH intake every 4-6 hours with dose adjustment to 
maintain an appropriate level of sedation. These patients also received scheduled 
lorazepam 2mg IV every 12 hours. The BZD dose was increased if patients remained 
symptomatic refractory to maximal EtOH therapy (defined as 100% of stated daily 
intake of EtOH, given every 4-6 hours, with scheduled 2mg BZD dose noted above).9  
Endpoints used for results analysis included complications as shown in Figure 
II. There was no significant difference in the complication rates between the 2 groups 
(p=0.564), though there was an overall trend towards decreased complication rates 
seen in the BZD with adjunctive EtOH group. Patients in the BZD group on average 
stayed for 1 extra hospital day compared to the BZD with adjunctive EtOH group 
(p=0.323).9 
DISCUSSION 
The future of EtOH in AWS management is unclear. The studies9,11 discussed 
above come to disparate conclusions with one study11 demonstrating BZD as the 
superior treatment modality, and the other suggesting EtOH, when used as an adjunct, 
 13 
may improve AWS management.9 Both studies have significant shortcomings that 
restrict the implications of their findings. Higher-powered studies are needed to 
develop definitive conclusions. 
In regard to Weinberg et al,11 there were several limitations that detracted from 
the study’s reliability. Using EtOH as a mono-therapy in the experimental group, 
rather than as an adjunct to BZD, may have lead to its decreased efficacy. 
Additionally, previous studies1 have established the importance of weight-based 
dosing of EtOH for AWS. The lack of such a dosing regimen in the Weinberg et al 
study11 may have lead to sub-therapeutic EtOH levels and subsequent decreased EtOH 
efficacy. The authors of the study acknowledged this problem and noted in their 
discussion that blood alcohol levels were undetectable in most of their patients using 
the study’s EtOH dosing regimen.  
The Weinberg et al study11 also did not fully disclose some of the patient 
demographics, which may have affected the results. This was particularly notable in 
that 8% of participants were identified as having experienced AWS in the past, though 
it was not identified which treatment groups these patients fell into. Given that 
patients with a history of previous AWS have the greatest risk for symptomatology, 
the lack of disclosure of which cohort these patients fell into may have confounded 
the results. 4  
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Both studies9,11 suffered from lack of blinding given that the study designs 
included alterations in therapy dosing regimens based on subjective findings (RSAS 
and Ramsey scale). This may have lead to sub or supra-therapeutic dosing regimens in 
either cohort. Additionally, this subjectivity may have influenced the results in the 
Weinberg et al study11 due to outcome measurements being derived from the same 
subjective scoring system.  
Specific patient populations were not appropriately represented in both 
studies.9,11 Critically-ill patients who were unable to provide informed consent were 
excluded from both of the studies, which unfortunately limits the implications of their 
results for acute care management. Female patients were also underrepresented, with 
93% male patients in the AWARE study and 96% male patients in the Weinberg et al 
study. Notably, the patients in the AWARE study were all post-MI, which presents its 
own assortment of mortality and morbidity risk factors that make the cohort not 
particularly representative of typical ICU patients.  
Perceived ethical implications have most likely contributed to the paucity of 
well-constructed studies evaluating therapeutic EtOH. It has been postulated that oral 
ethanol given by providers acts as a trigger for further alcohol addiction behavior and 
demonstrates permission by staff for continued abuse.3 This was particularly 
noticeable in the AWARE study,9 whose authors acknowledged discontinuity in 
support for therapeutic EtOH throughout the trial due to ethical concerns of certain 
 15 
providers and nursing staff. This bias against EtOH use lead to decreased patient 
enrollment and may have affected results of the trial.9 It can be surmised that personal 
ideologies surrounding alcoholism and addiction management may be detracting from 
both provider objectivity and the ability to treat AWS as a purely pathophysiologic 
process separate from the behavior of alcohol abuse. 
In order to definitively demonstrate the effectiveness, or lack thereof, of 
therapeutic EtOH, randomized controlled trials need to be done with large sample 
sizes. These studies would benefit from using weight-based dosing for EtOH to ensure 
therapeutic levels.1 It would most likely be beneficial for EtOH to be evaluated in the 
setting of adjunctive therapy to BZD rather than as mono-therapy given that current 
evidence leans towards the combination being more efficacious.9,11 Additionally, 
modifying EtOH delivery to either be via nasogastric tube or IV would help to negate 
possible behavior cues triggered by oral intake of therapeutic EtOH. Lastly, using the 
CIWA-Ar scale to evaluate response to therapy would bolster the applicability of 
future studies as it is the most commonly employed AWS symptom evaluation 
criteria.7 
CONCLUSION 
 There is not currently enough evidence to support or disavow the use of EtOH 
in the management of AWS. Of the two studies reviewed, the AWARE trial showed a 
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minor trend towards benefit in using EtOH as an adjunct for BZD therapy and 
Weinberg et al demonstrated BZD use as more effective than EtOH mono-therapy.  
Currently, more than 66% of major teaching hospitals in the United States have 
EtOH on their formulary and 70% of hospitals surveyed acknowledged that they have 
not constructed any specific guidelines for its administration.2,6 Between the 
numerous small population size studies demonstrating benefit of EtOH, and the 
frequency at which therapeutic EtOH is already being used, it is clear that a 
comprehensive study with a large population size is indicated to determine efficacy. 
Given the significant morbidity and mortality associated with AWS in the ICU 
setting, an evaluation of how providers can improve management of this condition is 
imperative.
 17 
References 
1. Ungur, L. A., Neuner, B., John, S., Wernecke, K., & Spies, C. (2013). Prevention and 
therapy of alcohol withdrawal on intensive care units: Systematic review of controlled 
trials.Alcoholism-Clinical and Experimental Research, 37(4), 675-686. 
doi:10.1111/acer.12002 
 
2. Dissanaike, S., Halldorsson, A., Frezza, E. E., & Griswold, J. (2006). An ethanol protocol 
to prevent alcohol withdrawal syndrome. Journal of the American College of 
Surgeons, 203(2), 186-191. doi:10.1016/j.jamcollsurg.2006.04.025 
 
3. DiPaula, B., Tommasello, A., Solounias, B., & McDuff, D. (1998). An evaluation of 
intravenous ethanol in hospitalized patients. Journal of Substance Abuse 
Treatment, 15(5), 437-442.  
 
4. Awissi, D., Lebrun, G., Coursin, D. B., Riker, R. R., & Skrobik, Y. (2013). Alcohol 
withdrawal and delirium tremens in the critically ill: A systematic review and 
commentary. Intensive Care Medicine, 39(1), 16-30. doi:10.1007/s00134-012-2758-y 
 
5. Bard, M. R., Goettler, C. E., Toschlog, E. A., Sagraves, S. G., Schenarts, P. J., Newell, 
M. A., et al. (2006). Alcohol withdrawal syndrome: Turning minor injuries into a major 
problem.Journal of Trauma-Injury Infection and Critical Care, 61(6), 1441-1445. 
doi:10.1097/01.ta.0000245981.22931.43 
 
6. Fisher, C. M. (2009). Prompt responses to the administration of ethanol in the treatment 
of the alcohol withdrawal syndrome (AWS). Neurologist, 15(5), 242-244. 
doi:10.1097/NRL.0b013e3181b47018 
 
7. Corfee, F. A. (2011). Alcohol withdrawal in the critical care unit. Australian Critical 
Care, 24(2), 110-116. doi:10.1016/j.aucc.2010.08.005 
 
8. Hodges, B., & Mazur, J. E. (2004). Intravenous ethanol for the treatment of alcohol 
withdrawal syndrome in critically ill patients. Pharmacotherapy:The Journal of Human 
Pharmacology & Drug Therapy, 24(11), 1578-1585.  
 
9. Fullwood, J. E., Mostaghimi, Z., Granger, C. B., Washam, J. B., Bride, W., Zhao, Y., et 
al. (2013). Alcohol withdrawal prevention: A randomized evaluation of lorazepam and 
ethanol--a pilot study. American Journal of Critical Care, 22(5), 398-406. 
doi:http://dx.doi.org.proxy.lib.pacificu.edu:2048/10.4037/ajcc2013283 
 
10. Walker, B., Anderson, M., Hauser, L., & Werchan, I. (2013). Ethanol for alcohol 
withdrawal: The end of an era (vol 74, pg 926, 2013). Journal of Trauma and Acute Care 
Surgery, 75(1), 185-185. 
 
 18 
11. Weinberg, J. A., Magnotti, L. J., Fischer, P. E., Edwards, N. M., Schroeppel, T., Fabian, 
T. C., et al. (2008). Comparison of intravenous ethanol versus diazepam for alcohol 
withdrawal prophylaxis in the trauma ICU: Results of a randomized trial. Journal of 
Trauma-Injury Infection & Critical Care, 64(1), 99-104. 
doi:http://dx.doi.org.proxy.lib.pacificu.edu:2048/10.1097/TA.0b013e31815eb12a 
 
12. GRADE working group. http://gradeworkinggroup.org. Accessed Jun 20 2016. 
 
  
 19 
Table I. Morbidity and Mortality associated with AWS5 
Hospital	Course	and	Complications	of	patients	with	AWS	compared	to	non-AWS	patients	
Length	of	ICU	stay	 +4.28	days	longer	stay	
Duration	of	ventilator	treatment	 +3.32	days	of	ventilation	
Total	length	of	stay	 +11.0	days	total	increased	length	of	stay	
Average	hospital	charges	 +316%	increased	cost	
Total	mortality	 +2.27%	incidence	
Respiratory	failure	 +22.4%	incidence	
Pneumonia	 +17.1%	incidence	
Sepsis	 +7.0%	incidence	
Need	for	tracheostomy	 +11.6%	incidence	
Need	for	percutaneous	endoscopic	gastrostomy	 +11.8%	incidence	
Table II. Characteristics of Reviewed Studies: GRADE Profile 
Quality Assessment 
 Downgrade Criteria Upgrade Quality 
Studies Design Limitations Indirectness Imprecision Inconsistency Publication 
Bias likely 
Weinberg, 
et al11 
RCT Seriousa 
 
Seriousb 
 
 
Seriousc 
 
Not Serious Not Serious None Very 
Low 
AWARE9 RCT Seriousa 
 
Not Serious Seriousc 
 
Not Serious Not Serious None Low 
aNon-blinded study using subjective patient assessments for determining treatment 
bLow starting dose of EtOH not comparable to control therapy of benzodiazepine 
cSmall patient size 
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Figure I. Summary of Findings: Weinberg et al.11 
 
 
 
 
 
 
 
 
 
Percentage	(%)	of	patients	deviating	from	RSAS	score	of	4	(calm	and	cooperative)	over	
their	course	of	treatment	
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Figure II. Summary of Findings: AWARE Study9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage	(%)	of	patients	who	had	various	complications	secondary	to	AWS	management	
with	either	BZD	or	BZD	with	adjunctive	EtOH	
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Appendix A: Riker Sedation-Agitation Scale11 
 
Value	 Description	
1	 Unarousable	
2		 Very	sedated	
3	 Sedated	
4	 Calm	and	cooperative	
5	 Agitated	
6	 Very	agitated	
7	 Dangerous	Agitation	
 
 
